Real-World Evidence of Safety and Efficacy of Carboplatin plus Nanoparticle Albumin-Bound Paclitaxel in Patients with Advanced Non-Small-Cell Lung Cancer and Preexisting Interstitial Lung Disease: A Retrospective Study

Table 1

Baseline patient characteristics.

Age, years
Median (range)	69 (59–79)
Gender
Male	8
Female	1
Smoking status
Current	3
Former	6
Preexisting interstitial lung disease
IPF	5
Non-IPF	4
ECOG performance status score
0-1	7
2	2
Disease stage
IIIB	2
IV	7
Tumor histology
Squamous cell carcinoma	7
Adenosquamous carcinoma	1
Pleomorphic carcinoma	1
EGFR mutation status
Wild type	9
ALK fusion genes
Negative	4
Unknown	5
KL-6 (U/mL)
Median (range)	659 (317–3890)
SP-D (ng/mL)
Median (range)	80.9 (43–174)
%FVC (%)
Median (range)	112.4 (53.8–124.2)
FEV1/FVC (%)
Median (range)	77.1 (56.4–92.4)
%DLco (%)
Median (range)	55.8 (29.1–76.6)
ILD-GAP index
Median (range)	4 (1–5)

IPF: idiopathic pulmonary fibrosis; ECOG: Eastern Cooperative Oncology Group; EGFR: epidermal growth factor receptor; ALK: anaplastic lymphoma kinase; FVC: forced vital capacity; FEV1: forced expiratory volume in one second; DLco: carbon monoxide diffusing capacity of the lung; ILD: interstitial lung disease; GAP: gender, age, and lung physiology variables.